SGLT-2 Inhibitors May Raise Risk for Diabetic Ketoacidosis
Risk for diabetic ketoacidosis increased compared with DPP-4 inhibitors; risk highest with canagliflozin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.